Tesamorelin costs between $800 and $1,500 per month for the standard 2mg daily dose used to treat HIV-associated lipodystrophy. Insurance coverage varies significantly, with Medicare Part D covering approximately 60% of the cost and private insurance plans showing coverage rates between 40-most depending on your specific policy. The FDA-approved peptide requires daily subcutaneous injections and comes as lyophilized powder that must be refrigerated. Brand name Egrifta SV dominates the market with limited generic alternatives available in 2026. Patient assistance programs through Theratechnologies can reduce monthly costs to $50-$150 for qualifying individuals with household incomes below $75,000 annually. Compounded versions from specialized pharmacies may cost $300-$600 monthly but lack FDA approval for this indication.
- Monthly tesamorelin costs range from $800-$1,500 for FDA-approved Egrifta SV
- Insurance coverage rates vary from 40-80% depending on your specific plan and diagnosis
- Patient assistance programs can reduce costs to $50-$150 monthly for eligible patients
- Compounded alternatives cost $300-$600 but aren't FDA-approved for HIV lipodystrophy
- The medication requires daily injections and proper refrigerated storage
FDA-Approved Tesamorelin Pricing in 2026
Egrifta SV remains the only FDA-approved tesamorelin formulation available in the United States, with pricing that reflects its specialty drug classification. A 30-day supply containing sixty 1mg vials costs between $2,400 and $4,500 at retail pharmacies, translating to the $800-$1,500 monthly patient cost after typical insurance coverage. The medication's pricing structure reflects both the limited patient population with HIV-associated lipodystrophy and the complex manufacturing requirements for this synthetic growth hormone-releasing hormone analog. Specialty pharmacies often provide better pricing than traditional retail locations. CVS Specialty, Walgreens Specialty, and independent specialty pharmacies typically offer the medication at the lower end of the pricing spectrum. The 30-day supply requires careful handling with refrigeration between 36-46°F throughout the supply chain, contributing to distribution costs.Insurance Coverage Patterns and Approval Rates
Insurance coverage for tesamorelin varies noticeableally based on your diagnosis and insurance type. For FDA-approved HIV-associated lipodystrophy treatment, Medicare Part D plans cover the medication with prior authorization in approximately most of cases. Private insurance approval rates range from 65-the vast majority for patients meeting clinical criteria, which includes documented visceral adipose tissue accumulation and HIV diagnosis. Commercial insurance plans typically place tesamorelin on specialty tier formularies, requiring 20-40% coinsurance rather than fixed copays. This means patients pay a percentage of the drug's cost rather than a flat fee. For patients with high-deductible health plans, the full retail cost may apply until the deductible is met, creating significant financial barriers early in the calendar year. Prior authorization requirements almost universally include documentation of HIV status, evidence of lipodystrophy through imaging or clinical assessment, and failure of lifestyle modifications. The approval process typically takes 7-14 business days, though expedited reviews are available for urgent cases.Patient Assistance and Financial Support Programs
Theratechnologies offers the Egrifta SV Patient Support Program, which provides substantial cost reductions for eligible patients. The program caps monthly patient responsibility at $50 for individuals with commercial insurance and household incomes below $75,000 annually. Patients with incomes between $75,000-$100,000 may qualify for partial assistance, reducing monthly costs to approximately $150. Medicare patients face different assistance options due to federal regulations prohibiting direct manufacturer support. However, state pharmaceutical assistance programs, local HIV/AIDS service organizations, and patient advocacy foundations often provide financial support. The Patient Access Network Foundation and Good Days Foundation maintain specific funds for HIV-related medications that may cover tesamorelin costs. Uninsured patients may qualify for the manufacturer's expanded access program, which can provide the medication at significantly reduced costs or free depending on financial circumstances. Applications require detailed financial documentation and physician attestation of medical necessity.Compounded Tesamorelin Alternatives and Pricing
Compounding pharmacies offer tesamorelin formulations at lower costs, typically ranging from $300-$600 monthly for equivalent dosing. These preparations are not FDA-approved for HIV lipodystrophy treatment but may be prescribed off-label by physicians familiar with peptide therapy applications. The cost difference reflects reduced regulatory requirements and direct-pay pricing models used by many compounding facilities. Quality and potency can vary significantly between compounding pharmacies. Reputable facilities follow USP <797> sterile compounding standards and provide certificates of analysis for each batch. However, the lack of FDA oversight means patients assume greater responsibility for verifying the medication's quality and appropriate storage. Some patients explore compounded tesamorelin for off-label uses including general growth hormone deficiency or body composition optimization. These applications fall outside FDA approval and insurance coverage, making cost a primary consideration for continued therapy.Geographic Pricing Variations and Pharmacy Options
Tesamorelin pricing varies by geographic region and pharmacy type. Urban areas with multiple specialty pharmacies often offer more competitive pricing compared to rural locations with limited options. West Coast and Northeast markets typically see the highest pricing, while Southeast and Midwest regions may offer modest savings. International pharmacy options exist but carry significant legal and safety risks. Canadian and European sources may offer lower pricing, but importation of prescription medications violates FDA regulations. temperature control during international shipping poses risks to medication stability and effectiveness. Mail-order specialty pharmacies frequently provide the best combination of pricing and convenience for ongoing therapy. These services include automatic refill programs, clinical support, and often superior insurance network participation compared to retail pharmacies.Budgeting Strategies and Cost Management
Annual healthcare budgeting becomes major for tesamorelin therapy given the high monthly costs. Patients should anticipate $10,000-$18,000 in annual medication costs before insurance coverage. Health Savings Account and Flexible Spending Account funds can cover copays and coinsurance, providing tax advantages for ongoing expenses. Generic competition remains limited in 2026, though biosimilar development continues. Patent protections for the current formulation extend through 2028, limiting near-term generic availability. Patients should plan for continued high costs through the remainder of the decade unless significant insurance changes occur. Some patients explore treatment interruptions or dose adjustments to manage costs, though this requires close physician supervision. Clinical studies suggest that benefits may diminish within 3-6 months of discontinuation, making consistent therapy important for maintaining results.Comparing Costs with Alternative Therapies
Alternative treatments for HIV lipodystrophy vary significantly in cost and effectiveness. Surgical options like liposuction for facial lipoatrophy may cost $3,000-$8,000 but require repeated procedures. Injectable fillers for facial volume restoration cost $1,500-$3,000 per treatment session with results lasting 12-18 months. Other growth hormone-releasing therapies like sermorelin or ipamorelin cost substantially less but lack FDA approval for HIV lipodystrophy treatment. These alternatives typically cost $200-$500 monthly but may not provide equivalent efficacy for visceral fat reduction. Lifestyle interventions including specialized exercise programs and nutritional counseling cost significantly less but show limited effectiveness for established lipodystrophy. Most insurance plans prefer documentation of lifestyle modification attempts before approving tesamorelin therapy.Frequently Asked Questions
Does insurance cover tesamorelin for off-label uses?
Insurance rarely covers tesamorelin for off-label uses like general growth hormone deficiency or body composition improvement. Coverage is typically limited to FDA-approved HIV-associated lipodystrophy treatment with proper documentation. Patients seeking off-label therapy usually pay full retail costs unless participating in clinical trials or research studies.
See transparent compounded pricing
Review compounded medication pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →View data table
| Category | Relative Cost Index | Detail |
|---|---|---|
| Brand Ozempic | 95 | $900-1,350/mo without insurance |
| Brand Wegovy | 90 | $1,300-1,600/mo without insurance |
| Brand Mounjaro | 88 | $1,000-1,200/mo without insurance |
| Compounded | 25 | $299-449/mo at FormBlends |
How long does tesamorelin treatment typically last?
Tesamorelin treatment duration varies based on individual response and treatment goals. Clinical studies demonstrate continued benefits with ongoing therapy, while discontinuation often leads to gradual return of visceral fat accumulation within 6-12 months. Most patients require indefinite treatment to maintain therapeutic benefits, making long-term cost planning essential.
Can I get tesamorelin from compounding pharmacies safely?
Compounded tesamorelin can be obtained safely from reputable facilities following USP standards, but quality varies significantly between pharmacies. Patients should verify proper licensing, sterile compounding capabilities, and batch testing procedures. While less expensive, compounded versions lack FDA oversight and may have different potency or stability characteristics compared to approved formulations.
What documentation do I need for insurance approval?
Insurance approval typically requires HIV diagnosis confirmation, evidence of lipodystrophy through physical examination or imaging, documentation of failed lifestyle interventions, and physician attestation of medical necessity. Some plans also require baseline metabolic parameters including glucose levels and cardiovascular risk assessment before approving therapy.
Are there generic versions of tesamorelin available?
No generic versions of tesamorelin are currently available in the United States. Patent protections for Egrifta SV extend through 2028, preventing generic competition until at least 2029. Biosimilar development is ongoing but faces regulatory challenges due to the complex peptide structure and manufacturing requirements.
How does tesamorelin cost compare to other peptide therapies?
Tesamorelin is among the most expensive peptide therapies available, significantly higher than BPC-157 or TB-500 alternatives. The FDA approval status and limited patient population contribute to premium pricing. Other growth hormone-related peptides cost 60-most less but lack equivalent regulatory approval and clinical evidence for lipodystrophy treatment.
Can Medicare patients get manufacturer assistance for tesamorelin?
Medicare patients cannot receive direct manufacturer copay assistance due to federal anti-kickback regulations. However, they may qualify for support through Patient Access Network Foundation, Good Days Foundation, or state pharmaceutical assistance programs. These programs operate independently of manufacturers and can provide substantial cost relief for eligible patients.
What happens if I can't afford tesamorelin treatment?
Patients unable to afford tesamorelin should explore manufacturer patient assistance programs, disease-specific foundations, and local HIV service organizations. Some academic medical centers offer clinical trials or expanded access programs. Also, some physicians may recommend alternative treatments or modified dosing schedules to reduce costs while maintaining some therapeutic benefit.
Sources
- Stanley TL, et al. Effect of tesamorelin on visceral fat in HIV patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038356
- Falutz J, et al. Effects of tesamorelin on body composition and quality of life in HIV patients with abdominal fat accumulation. AIDS. 2010;24(18):2827-2837. PMID: 20966636
- Theratechnologies Inc. Egrifta SV prescribing information. 2022. FDA Orange Book Database.
- Centers for Medicare & Medicaid Services. Coverage determinations for growth hormone releasing hormone analogs. 2023.
- Patient Access Network Foundation. HIV medication assistance program guidelines. 2026.
- USP. General Chapter <797> Pharmaceutical Compounding Sterile Preparations. 2019.
- AIDS Healthcare Foundation. HIV lipodystrophy treatment access and affordability report. 2025.
- Institute for Clinical and Economic Review. Tesamorelin cost-effectiveness analysis for HIV lipodystrophy. 2024.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →